Clinical Trials Logo

Filter by:
NCT ID: NCT05296005 Not yet recruiting - Clinical trials for Gastric Adenocarcinoma

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Start date: May 31, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety, side effects studies chemotherapy followed by chemotherapy at the same time as radiation therapy (chemoradiation) before surgery (neoadjuvant) in treating patients with stage gastric (stomach) or gastroesophageal junction cancer . Chemotherapy drugs, such as docetaxel, oxaliplatin , leucovorin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy and chemoradiation before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT05295706 Not yet recruiting - Type 2 Diabetes Clinical Trials

Towards Understanding the Relationship Between Meals and Blood Biomarkers

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to establish the reasonableness of using food-based photo diaries and continuous glucose monitors (CGM) to engage in counterfactual thinking strategies. These strategies may improve food choices among participants diagnosed with prediabetes (intervention group).

NCT ID: NCT05292053 Not yet recruiting - Copd Clinical Trials

Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

Sundial-COPD
Start date: April 1, 2022
Phase: Phase 4
Study type: Interventional

This is a single-center, prospective, open-label study evaluating outcomes of TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder) on PRN nebulized short-acting beta agonist (SABA) treatment in hospitalized subjects with COPD with or without asthma. Approximately 80 adult subjects with COPD with or without asthma will take part in this study at this location. Subjects will be given TRELEGY ELLIPTA, placed on a consistent short-term systemic corticosteroid therapy, and followed until 30 days post hospital discharge. This study will not include patients with rapidly deteriorating or potentially life-threatening episodes of COPD or asthma.

NCT ID: NCT05289609 Not yet recruiting - Clinical trials for Liver Transplant Disorder

Developing Prediction Models for Allograft Failure After Liver Transplantation

IMPROVEMENT
Start date: April 1, 2022
Phase:
Study type: Observational

Prompt identification of allograft failure (AF) is highly desirable to address patients to liver retransplantation, in order to maximize results and preserve patients safety. Recently, sophisticated kinetic models became available, offering the possibility to predict 90-day AF with unprecedented accuracy, by computing data from the first 10 days after liver transplant (LT). The growing utilization of extended criteria and cardiac death donors stimulates the transplant community to further refine such predictive models and validate them on a larger scale population of patients across the nations. This study aims to develop new algorithms for the timely prediction of AF at 90 and 365 days using a prospective international cohort from high-volume centers, to validate them on a large retrospective cohort, to identify the best time for retransplantation, to stratify the risk of AF according to the graft type (i.e. DBD, ECD, DCD, LD), to weigh the effect of risk-mitigation strategies, and to assess the correlation with post-LT morbidity and mortality.

NCT ID: NCT05288959 Not yet recruiting - Healthy Clinical Trials

Modeling TMS-induced Cortical Network Activity

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

This is a study of normal brain physiology in healthy human volunteers. The study aims to understand the physiology of connectivity between brain regions. To reach this aim, it delivers single-pulse transcranial magnetic stimulation (spTMS) to one or two brain areas at a time while electroencephalography (EEG) is measured. When only one brain area is stimulated (uni-focal TMS), the goal is to record how many milliseconds it takes for the activity to spread from the stimulated area to other brain regions (conduction delay). When two brain areas are stimulated (bi-focal TMS), the TMS pulses are separated by a short millisecond-level time interval ("asynchrony") in a so-called paired associative stimulation (PAS) design. The central hypothesis is that PAS may increase or decrease connectivity between the stimulated areas depending on the asynchrony value. All techniques in the study are non-invasive and considered safe.

NCT ID: NCT05288725 Not yet recruiting - Clinical trials for Osteoarthritis, Knee

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

Start date: August 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a multicentered, randomized, double-blinded, placebo-controlled study conducted on the unilateral knee of 120 patients. The study compares the effectiveness of an injection of a mesenchymal stem cell preparation from autologous bone marrow aspirate (BMA) to a corticosteroid control for knee osteoarthritis. WOMAC, VAS pain scores, and MRI will be used for assessment. The study will be conducted at 3 sites in the United States.

NCT ID: NCT05288595 Not yet recruiting - Clinical trials for Hematologic Malignancy

TCR Alpha/Beta and CD19-deplete Haplo-HSCT

Start date: December 2024
Phase: Phase 2
Study type: Interventional

This is an open label, interventional, non-randomized, phase II trial of TCR alpha/beta and CD19-depeleted allogeneic HCT in pediatric patients with hematologic disease.

NCT ID: NCT05287347 Not yet recruiting - Clinical trials for Pancreatic Adenocarcinoma

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

Start date: October 2024
Phase:
Study type: Observational

The purpose of this study is to test a double screening strategy for pancreatic cancer, based on a model developed using patient medical records. Investigators would also like to test whether adding specific blood tests, can further help identify people who have a higher risk of pancreatic cancer than the general population, and would benefit from imaging in order to detect cancer early.

NCT ID: NCT05286840 Not yet recruiting - Prostate Cancer Clinical Trials

64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

Start date: March 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This research project is testing a new compound which may potentially detect specific cancer lesions in men with prostate cancer.

NCT ID: NCT05286255 Not yet recruiting - COVID-19 Pneumonia Clinical Trials

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

SAMPSON-1
Start date: September 2024
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1 clinical trial of allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia will be given 2 doses of MSCs at days 1 and 3 after consent. The safety of intravenous infusion will be tested and course of the oxygen response to treatment over 90 days will be evaluated.